Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery - PubMed (original) (raw)
Clinical Trial
. 1980 Dec 4;303(23):1323-9.
doi: 10.1056/NEJM198012043032303.
S B Green, D P Byar, E Alexander Jr, U Batzdorf, W H Brooks, W E Hunt, C S MacCarty, M S Mahaley Jr, J Mealey Jr, G Owens, J Ransohoff 2nd, J T Robertson, W R Shapiro, K R Smith Jr, C B Wilson, T A Strike
- PMID: 7001230
- DOI: 10.1056/NEJM198012043032303
Clinical Trial
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
M D Walker et al. N Engl J Med. 1980.
Abstract
Within three weeks of definitive surgical intervention, 467 patients with histologically proved malignant glioma were randomized to receive one of four treatment regimens: semustine (MeCCNU), radiotherapy, carmustine (BCNU) plus radiotherapy, or semustine plus radiotherapy. We analyzed the data for the total randomized population and for the 358 patients in whom the initial protocol specifications were met (the valid study group). Observed toxicity included acceptable skin reactions secondary to radiotherapy and reversible leukopenia and thrombocytopenia due to chemotherapy. Radiotherapy used alone or in combination with a nitrosourea significantly improved survival in comparison with semustine alone. The group receiving carmustine plus radiotherapy had the best survival, but the difference in survival between the groups receiving carmustine plus radiotherapy and semustine plus radiotherapy was not statistically significant. The combination of carmustine plus radiotherapy produced a modest benefit in long-term (18-month) survival as compared with radiotherapy alone, although the difference between survival curves was not significiant at the 0.05 level. This study suggests that it is best to use radiotherapy in the post-surgical treatment of malignant glioma and to continue the search for an effective chemotherapeutic regimen to use in addition to radiotherapy.
Similar articles
- Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, Mealey J Jr, Odom GL, Paoletti P, Ransohoff J 2nd, Robertson JT, Selker RG, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA. Green SB, et al. Cancer Treat Rep. 1983 Feb;67(2):121-32. Cancer Treat Rep. 1983. PMID: 6337710 Clinical Trial. - [Evaluation of ACNU alone and combined with tegafur as additions to radiotherapy of the treatment of malignant gliomas--a cooperative clinical trial].
Ushio Y, Abe H, Suzuki J, Tanaka R, Kitamura K, Miwa T, Matsutani M, Takeuchi K, Takakura K, Nomura K, et al. Ushio Y, et al. No To Shinkei. 1985 Oct;37(10):999-1006. No To Shinkei. 1985. PMID: 3000412 Clinical Trial. Japanese. - [Clinical significance of mustoforan in management of malignant glioma].
Kobiakov GL. Kobiakov GL. Vopr Onkol. 2007;53(6):724-9. Vopr Onkol. 2007. PMID: 18416147 Review. Russian. No abstract available. - The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L. Tsao MN, et al. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):47-55. doi: 10.1016/j.ijrobp.2005.05.024. Int J Radiat Oncol Biol Phys. 2005. PMID: 16111571 Review.
Cited by
- Multi-modal fusion and feature enhancement U-Net coupling with stem cell niches proximity estimation for voxel-wise GBM recurrence prediction.
Jiao C, Lao Y, Zhang W, Braunstein S, Salans M, Villanueva-Meyer J, Hervey-Jumper SL, Yang B, Morin O, Valdes G, Fan Z, Shiroishi M, Zada G, Sheng K, Yang W. Jiao C, et al. Phys Med Biol. 2024 Jul 25;69(15):10.1088/1361-6560/ad64b8. doi: 10.1088/1361-6560/ad64b8. Phys Med Biol. 2024. PMID: 39019073 - DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
Rahman R, Shi DD, Reitman ZJ, Hamerlik P, de Groot JF, Haas-Kogan DA, D'Andrea AD, Sulman EP, Tanner K, Agar NYR, Sarkaria JN, Tinkle CL, Bindra RS, Mehta MP, Wen PY. Rahman R, et al. Neuro Oncol. 2024 Aug 5;26(8):1367-1387. doi: 10.1093/neuonc/noae072. Neuro Oncol. 2024. PMID: 38770568 Review. - State of the neoadjuvant therapy for glioblastoma multiforme-Where do we stand?
Nabian N, Ghalehtaki R, Zeinalizadeh M, Balaña C, Jablonska PA. Nabian N, et al. Neurooncol Adv. 2024 Mar 5;6(1):vdae028. doi: 10.1093/noajnl/vdae028. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38560349 Free PMC article. Review. - Perioperative dexamethasone in high-grade gliomas: the short-term benefits and long-term harms.
Mistry AM. Mistry AM. Front Oncol. 2023 Dec 14;13:1335730. doi: 10.3389/fonc.2023.1335730. eCollection 2023. Front Oncol. 2023. PMID: 38162484 Free PMC article. - Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors.
Crompton D, Koffler D, Fekrmandi F, Lehrer EJ, Sheehan JP, Trifiletti DM. Crompton D, et al. J Neurooncol. 2023 Oct;165(1):21-28. doi: 10.1007/s11060-023-04466-5. Epub 2023 Oct 27. J Neurooncol. 2023. PMID: 37889441 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous